ClinicalTrials.gg
CompletedNCT06817356Updated Jul 16, 2026

A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

A Phase 2 interventional study of Mazdutide and Placebo in Alcohol Use Disorder, sponsored by Eli Lilly and Company. Completed at 25 sites in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,073 studies in Alcoholism with a site in United States — 187 open to participants now, 227 under way, 15 of them phase 3. Alcoholism · United States.

Enrollment
117th of 989
308 · median 80
Started
2025
with 55 others
Phase 2
247 of 1,073
38 open now
Registered
993rd of 1,073
by date

Among the 1,073 studies in Alcoholism with a site in United States, this one is the 117th largest by enrollment of the 989 interventional ones that give a count, is one of 56 that started in 2025, is one of 247 in phase 2, and was the 993rd registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

187 of the 1,073 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:

182 more — sign in →

All 187 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,073 studies in Alcoholism with a site in United States, or all of them as a file.
02

Study summary

The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD).

For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.

03

Conditions studied

  • Alcohol Use Disorder

Browse trials for

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current AUD diagnosis as defined by (DSM)-5 criteria.

Exclusion criteria

Exclusion Criteria:

  • Have a history of significant active or unstable major depressive disorder, suicidal ideation, or other severe psychiatric disorder within the last 12 months.
  • Have initiated psychotherapy, changed the intensity of psychotherapy, or other nondrug therapies (for example, acupuncture or hypnosis) within 8 weeks prior to enrollment.
  • Have received any medication for AUD in the last 30 days including but not limited to, disulfiram, acamprosate, naltrexone, gabapentin, baclofen, or topiramate.
  • Other protocol-specific inclusion and exclusion criteria may apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
308 participants (actual)

Study arms

  • Experimental
    Mazdutide

    Mazdutide administered subcutaneously (SC).

    Drug: Mazdutide

  • Placebo comparator
    Placebo

    Placebo administered SC.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3305677

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method

    Time frame: Baseline, Week 28

07

Study locations

25 sites
  • Headlands Research - Scottsdale
    Scottsdale, Arizona 85260, United States
  • Woodland Resarch Northwest/ERG
    Rogers, Arkansas 72758, United States
  • Ark Clinical Research - Fountain Valley
    Fountain Valley, California 92708, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • Headlands Research-Artemis San Diego
    San Diego, California 92123, United States
  • Research Centers of America ( Hollywood )
    Hollywood, Florida 33024, United States
  • K2 Medical Research - Maitland
    Maitland, Florida 32751, United States
  • K2 Medical Research
    Maitland, Florida 32751, United States
  • Clinical Neuroscience Solutions Inc
    Orlando, Florida 32801, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • K2 Medical Research - Tampa
    Tampa, Florida 33634, United States
  • CenExel iResearch, LLC (CenExel iRA)
    Decatur, Georgia 30030, United States
  • DelRicht Research
    Mandeville, Louisiana 70471, United States
  • Adams Clinical
    Watertown, Massachusetts 02472, United States
  • Vitalix Clinical
    Worcester, Massachusetts 01608, United States
  • Redbird Research LLC
    Las Vegas, Nevada 89119, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10314, United States
  • Ichor Research
    Syracuse, New York 13210, United States
  • Davis Clinical
    The Bronx, New York 10461, United States
  • Summit Headlands
    Portland, Oregon 97210, United States
  • Rhode Island Mood & Memory Research Institute
    East Providence, Rhode Island 02914, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Clinical Neuroscience Solutions Inc
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials of Dallas
    Dallas, Texas 75251, United States
  • Dallas Clinical Research Center/Pillar Research
    Richardson, Texas 75080, United States
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Mar 2026, 13 months.

Of 134 phase 2 interventional studies under Alcoholism, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 10, 2025
StartActual
Feb 6, 2025
Primary completionActual
Mar 19, 2026
CompletionActual
May 19, 2026
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06817356
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Feb 6, 2025
Primary completion
Mar 19, 2026
Completion
May 19, 2026
Last update
Jul 16, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion